A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Pratītyasamutpāda (Sanskrit: प्रतीत्यसमुत्पाद, Pāli: paṭiccasamuppāda), commonly translated as dependent origination, or dependent arising, is a key doctrine in Buddhism shared by all schools of Buddhism. It states that all conditioned dharmas (phenomena) arise in dependence upon other dharmas: "if this exists, that exists; if this ceases to exist, that also ceases to exist". The basic principle is that all conditioned things (saṅkhata dharmas, conditioned phenomena, conditioned principles) arise in dependence upon other things. The doctrine includes depictions of the arising of suffering (anuloma-paṭiccasamuppāda, "with the grain", forward conditionality) and depictions of how the chain can be reversed (paṭiloma-paṭiccasamuppāda, "against the grain", reverse conditionality). These processes are expressed in various lists of dependently originated phenomena, the most well-known of which is the twelve links or nidānas (Pāli: dvādasanidānāni, Sanskrit: dvādaśanidānāni). The traditional interpretation of these lists is that they describe the process of a sentient being's rebirth in saṃsāra, and the resultant duḥkha (suffering, pain, unsatisfactoriness), and they provide an analysis of rebirth and suffering that avoids positing an atman (unchanging self or eternal soul). The reversal of the causal chain is explained as leading to the cessation of rebirth (and thus, the cessation of suffering). Another interpretation regards the lists as describing the arising of mental processes and the resultant notion of "I" and "mine" that leads to grasping and suffering.
Purkinje cell dendrites Smooth endoplasmic reticulum Cell membrane Periglomerular cells in the olfactory bulb Cerebellar cortex Neurons in the brainstem, entorhinal and piriform cortices, and the habenula.
== Interactions == Blood plasma concentrations may be increased when combined with CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, ritonavir, and voriconazole) possibly leading to more side effects. This has been clinically verified for ketoconazole, which increases lurasidone exposure by a factor of 9, and is also expected for other 3A4 inhibitors such as grapefruit juice. Co-administration of CYP3A4 inducers like rifampicin, carbamazepine or St. John's wort can reduce plasma levels of lurasidone and its active metabolite, and consequently decrease the effects of the drug. For rifampicin, the reduction was sixfold in a study.
A point accepted mutation — also known as a PAM — is the replacement of a single amino acid in the primary structure of a protein with another single amino acid, which is accepted by the processes of natural selection. This definition does not include all point mutations in the DNA of an organism. In particular, silent mutations are not point accepted mutations, nor are mutations that are lethal or that are rejected by natural selection in other ways. A PAM matrix is a matrix where each column and row represents one of the twenty standard amino acids. In bioinformatics, PAM matrices are sometimes used as substitution matrices to score sequence alignments for proteins. Each entry in a PAM matrix indicates the likelihood of the amino acid of that row being replaced with the amino acid of that column through a series of one or more point accepted mutations during a specified evolutionary interval, rather than these two amino acids being aligned due to chance. Different PAM matrices correspond to different lengths of time in the evolution of the protein sequence.
Sources: en.wikipedia.org
== Circulation and mixing == The stratosphere is a region of intense interactions among radiative, dynamical, and chemical processes, in which the horizontal mixing of gaseous components proceeds much more rapidly than does vertical mixing. The overall circulation of the stratosphere is termed as Brewer-Dobson circulation, which is a single-celled circulation, spanning from the tropics up to the poles, consisting of the tropical upwelling of air from the tropical troposphere and the extra-tropical downwelling of air. Stratospheric circulation is a predominantly wave-driven circulation in that the tropical upwelling is induced by the wave force by the westward propagating Rossby waves, in a phenomenon called Rossby-wave pumping. An interesting feature of stratospheric circulation is the quasi-biennial oscillation (QBO) in the tropical latitudes, which is driven by gravity waves that are convectively generated in the troposphere. The QBO induces a secondary circulation that is important for the global stratospheric transport of tracers, such as ozone or water vapor. Another large-scale feature that significantly influences stratospheric circulation is the breaking planetary waves resulting in intense quasi-horizontal mixing in the midlatitudes. This breaking is much more pronounced in the winter hemisphere where this region is called the surf zone. This breaking is caused due to a highly non-linear interaction between the vertically propagating planetary waves and the isolated high potential vorticity region known as the polar vortex.
4-HO-MET, also known as 4-hydroxy-N-methyl-N-ethyltryptamine, as well as metocin or methylcybin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It is a close structural analogue of psilocin (4-HO-DMT) and is the 4-hydroxyl analogue of methylethyltryptamine (MET). 4-HO-MET was discovered by Alexander Shulgin in the 1970s. It was first described in the literature by David Repke and colleagues in 1981. The drug was encountered as a novel recreational and designer drug by 2008. It is openly sold as a legal recreational drug in the United States.
c) Shows that it is more likely than not that Mr Galloway knew about and was complicit in what was happening. The Commissioner stated that he did not have "access to bank accounts held either solely by Mr Galloway or jointly by him with others".
== Production and distribution == Entire illicit supply chains dedicated to collecting, processing, and reselling gutter oil have been discovered by regulators in China. Multiple low-end restaurants in China have been found to cook with gutter oil. Additionally, in 2012, the Chinese government accused a Chinese pharmaceutical company of using gutter oil as a precursor for the manufacturing of cephalosporin antibiotics. About two to three million tons of cooking oil containing cancerous substances are produced in China each year. In 2010 it was estimated that approximately one tenth of the meals consumed by people in China could contain gutter oil. Collected waste oil is sold to local workshops or small factories for cleaning and packaging. When sold to workshops it is often transported by bicycle mounted collectors; afterwards, the oil is held in 200-liter barrels at the workshops until it is processed. On other occasions the oil goes to industrial cooking oil refineries for further processing before it finally reaches its end purpose. Reprocessing of used cooking oil is often very rudimentary; techniques include filtration, boiling, refining, and the removal of some adulterants. It is then packaged and resold as a cheaper alternative to normal cooking oil. Another version of gutter oil uses discarded animal parts, animal fat and skins, internal organs, and expired or otherwise low-quality meat, which is then cooked in large vats to extract the oil. Some lower-market restaurants have long-term purchase agreements with oil recyclers for selling their used oil.
Biting the fingers and lips is a definitive feature of Lesch–Nyhan syndrome; in other syndromes associated with self-injury, the behaviors usually consist of head banging and nonspecific self-mutilation, but not biting of the cheeks, lips and fingers. Lesch–Nyhan syndrome ought to be clearly considered only when self-injurious behavior takes place in conjunction with hyperuricemia and neurological dysfunction.
Sources: en.wikipedia.org
== Early life, education, and career == Wittman was born in Washington, D.C., the son of adoptive parents Regina C. (née Wood) and Frank Joseph Wittman. His father was of German descent and his mother's ancestors included immigrants from Ireland and Canada. He grew up in Henrico County, Virginia. He attended the Virginia Polytechnic Institute and State University (Virginia Tech) as a member of the Corps of Cadets and Army ROTC and studied biology. While at Virginia Tech, he spent the summers working at a tomato cannery and on a fishing vessel. Also while in college, Wittman was a member of the Delta Tau Delta fraternity. He earned a master's degree in public health from the University of North Carolina at Chapel Hill in 1990 and a Ph.D. from Virginia Commonwealth University in 2002. Wittman worked for 20 years with the Virginia Department of Health. He served as an environmental health specialist and was field director for the Division of Shellfish Sanitation. Wittman served on the Montross Town Council from 1986 to 1996 and as mayor of the Town of Montross from 1992 to 1996. Two of his major initiatives in this office were the overhaul of the sewage system and the development of a computerized system for tax billing. From 1996 to 2005, Wittman served on the Westmoreland County Board of Supervisors, the last two years as chair. He helped create new libraries and pushed for raises in teacher salaries.
While not as life-threatening as a bite from a venomous species, the bite can be at least temporarily debilitating and could lead to dangerous infections if improperly dealt with. While most snakes must open their mouths before biting, African and Middle Eastern snakes belonging to the family Atractaspididae can fold their fangs to the side of their head without opening their mouth and jab a person.
The city was developed on the land of various plantations including Crabtree, Mordecai, Oak View, Pine Hall, Pullen, Spring Hill, and Wakefield. The North Carolina General Assembly first met in Raleigh in December 1794, and granted the city a charter, with a board of seven appointed commissioners and an "Intendant of Police" (which developed as the office of Mayor) to govern it. After 1803, city commissioners were elected. In 1799, the N.C. Minerva and Raleigh Advertiser was the first newspaper published in Raleigh. John Haywood was the first Intendant of Police.
==== MeSH D06.472.334 – gonadal hormones ==== MeSH D06.472.334.500 – activins MeSH D06.472.334.500.500 – inhibin-beta subunits MeSH D06.472.334.734 – corpus luteum hormones MeSH D06.472.334.734.623 – progesterone MeSH D06.472.334.734.769 – relaxin MeSH D06.472.334.851 – gonadal steroid hormones MeSH D06.472.334.851.437 – estradiol congeners MeSH D06.472.334.851.437.249 – equilenin MeSH D06.472.334.851.437.374 – equilin MeSH D06.472.334.851.437.500 – estradiol MeSH D06.472.334.851.437.750 – estriol MeSH D06.472.334.851.437.750.320 – estetrol MeSH D06.472.334.851.437.968 – estrogenic steroids, alkylated MeSH D06.472.334.851.437.968.500 – ethinyl estradiol MeSH D06.472.334.851.437.968.500.250 – ethinyl estradiol-norgestrel combination MeSH D06.472.334.851.437.968.500.500 – mestranol MeSH D06.472.334.851.437.968.500.750 – quinestrol MeSH D06.472.334.851.437.984 – estrogens, catechol MeSH D06.472.334.851.437.984.350 – hydroxyestrones MeSH D06.472.334.851.437.988 – estrogens, conjugated (usp) MeSH D06.472.334.851.437.994 – estrogens, esterified (usp) MeSH D06.472.334.851.437.996 – estrone MeSH D06.472.334.851.687 – progesterone congeners MeSH D06.472.334.851.687.500 – pregnenolone MeSH D06.472.334.851.687.500.500 – 17-alpha-hydroxypregnenolone MeSH D06.472.334.851.687.750 – progesterone MeSH D06.472.334.851.687.750.074 – 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 – 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 – hydroxyprogesterones MeSH D06.472.334.851.687.750.478.400 – 17-alpha-hydroxyprogesterone MeSH D06.472.334.851.687.750.478.400.500 – pregnanetriol MeSH D06.472.334.851.687.750.739 – pregnanediol MeSH D06.472.334.851.968 – testosterone congeners MeSH D06.472.334.851.968.500 – androstane-3,17-diol MeSH D06.472.334.851.968.750 – androstenediol MeSH D06.472.334.851.968.875 – androstenedione MeSH D06.472.334.851.968.937 – androsterone MeSH D06.472.334.851.968.952 – dehydroepiandrosterone MeSH D06.472.334.851.968.952.300 – dehydroepiandrosterone sulfate MeSH D06.472.334.851.968.964 – dihydrotestosterone MeSH D06.472.334.851.968.968 – etiocholanolone MeSH D06.472.334.851.968.976 – nandrolone MeSH D06.472.334.851.968.984 – testosterone MeSH D06.472.334.851.968.984.500 – epitestosterone MeSH D06.472.334.851.968.984.750 – testosterone propionate MeSH D06.472.334.968 – inhibins MeSH D06.472.334.968.500 – inhibin-beta subunits MeSH D06.472.334.984 – testicular hormones
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.